RaySearch Laboratories awarded a major tender for its RayStation in Quebec, Canada.
M2 PHARMA-July 19, 2018-RaySearch Laboratories awarded a major tender for its RayStation in Quebec, Canada
(C)2018 M2 COMMUNICATIONS
Medical technology company RaySearch Laboratories AB (STO:RAYB) announced on Wednesday that its RayStation has been chosen as the primary treatment planning system through a tender process, replacing the current treatment planning systems at the Centre integre universitaire de sante et de services sociaux de l'Estrie-Centre hospitalier universitaire de Sherbrooke, in Quebec, Canada.
This centre treats approximately 2000 cancer patients a year and is equipped with four linear accelerators.
This purchase, financial details of which were not available, consist of a wide array of modules, including multi-criteria optimisation, Plan Explorer, AutoBreast planning and full support for adaptive radiotherapy. The full installation supports approximately 20 simultaneous users.
According to the company, the majority of this order has been delivered and will generate revenue in the second quarter of 2018.
RayStation integrates all RaySearch's advanced treatment planning solutions into a flexible treatment planning system. It combines features such as multi-criteria optimisation tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch's algorithms for IMRT and VMAT optimisation and highly accurate dose engines for photon, electron, proton and carbon ion therapy.
RaySearch Laboratories, a developer of software solutions for improved cancer treatment, markets the RayStation treatment planning system and the RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 19, 2018|
|Previous Article:||eviCore healthcare announces St. Louis as its new service centre of healthcare providers.|
|Next Article:||Asceneuron SA passes US FDA's ODD for ASN120290 for treating progressive supranuclear palsy (PSP).|